NeoTRACE

A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer

II

interventionell

National

Sacituzumab govitecan (SG) is a novel antibody drug conjugate (ADC) combining the humanized RS7 antibody targeting Trop-2 coupled to a hydrolysable linker that allows for a time dependent release of the payload to deliver SN-38, the active metabolite of irinotecan to tumor tissue. Zimberelimab (ZIM) is a fully human, IgG4 monoclonal antibody that binds PD-1 on T cells and NK cells, preventing PD-L1-mediated immunosuppressive effects and resulting in enhanced tumor cell death.

Status: In Vorbereitung

Zeitraum

2025

2031

Zentren

15

Auf Anfrage

Patienten

50

19.06.2024

Klinische Settings

II, IIA, IIB, IIC, III, IIIA, IIIB

peri-operativ

1st line

kurativ

Beteiligte

AIO-Arbeitsgruppen

Sponsor

AIO-Studien-gGmbH

Förderer

Gilead Sciences, Inc.

Identifier

AIO-TRK-0224

Kontakt

Leitung

Dr. med. Friederike Althoff

Ansprechpartner*in

Dr. med. Friederike Althoff
E-Mail falthoff@med.uni-frankfurt.de